{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:43:26Z","timestamp":1778867006200,"version":"3.51.4"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/iae.0b013e318275394a","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T06:38:07Z","timestamp":1351147087000},"page":"329-338","source":"Crossref","is-referenced-by-count":101,"title":["LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up"],"prefix":"10.1097","volume":"33","author":[{"given":"Mar\u00eda A.","family":"Mart\u00ednez-Castellanos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shulamit","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam L.","family":"Hern\u00e1ndez-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica A.","family":"Kon-Jara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Garc\u00eda-Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Guerrero-Naranjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. V. Paul","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Quiroz\u2013Mercado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(97)01107-0","article-title":"Retinopathy of prematurity in middle-income countries.","volume":"350","author":"Gilbert","year":"1997","journal-title":"Lancet"},{"key":"R2-11-20210130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00055735-200310000-00009","article-title":"Retinopathy of prematurity.","volume":"14","author":"Hutchenson","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":". Incidence and early course of retinopathy of prematurity.","volume":"98","author":"Earl","year":"1991","journal-title":"Ophthalmology"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","article-title":". Childhood blindness.","volume":"3","author":"Steinkuller","year":"1999","journal-title":"J AAPOS"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2009.04.018","article-title":"Incidence of retinopathy of prematurity in the United States: 1997 through 2005.","volume":"148","author":"Lad","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control.","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"R7-11-20210130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results.","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"R8-11-20210130","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R9-11-20210130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/eye.1992.46","article-title":"Natural history of retinopathy of prematurity: a prospective study.","volume":"6","author":"Fielder","year":"1992","journal-title":"Eye"},{"key":"R10-11-20210130","first-page":"576","article-title":"Variable oxygen exposure causes preretinal neovascularization in the newborn rat.","volume":"34","author":"Penn","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","article-title":"Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.","volume":"114","author":"Pierce","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R12-11-20210130","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP.","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","article-title":". Vascular endothelial growth and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.","volume":"156","author":"Lashkari","year":"2000","journal-title":"Am J Pathol"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bjo.2007.128371","article-title":". VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity.","volume":"92","author":"Pieh","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R15-11-20210130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1542\/neo.4-12-e356","article-title":"Angiogenesis and antiangiogenesis in the neonate: relevance to retinopathy of prematurity.","volume":"4","author":"Madan","year":"2003","journal-title":"Neoreviews"},{"key":"R16-11-20210130","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.ophtha.2005.09.018","article-title":"Growth factor levels and ROP.","volume":"112","author":"Villegas","year":"2005","journal-title":"Ophthalmology"},{"key":"R17-11-20210130","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","article-title":". Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia.","volume":"15","author":"Stone","year":"1995","journal-title":"J Neurosci"},{"key":"R18-11-20210130","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":". Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"R19-11-20210130","first-page":"290","article-title":". Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity.","volume":"37","author":"Stone","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-11-20210130","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.","volume":"28","author":"Mintz","year":"2008","journal-title":"Retina"},{"issue":"suppl","key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":". Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":". Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"R23-11-20210130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/08820530701420082","article-title":". Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.","volume":"22","author":"Quiroz-Mercado","year":"2007","journal-title":"Semin Ophthalmol"},{"key":"R24-11-20210130","first-page":"207","article-title":"Laser-ranibizumab treatment for retinopathy of prematurity in threshold-prethreshold disease. A 3-year experience in Spanish.","volume":"79","author":"Orozco-Gomez","year":"2011","journal-title":"Cir Cir"},{"key":"R25-11-20210130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity.","volume":"64","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R26-11-20210130","first-page":"9288","article-title":"Will the BEAT-ROP study results really beat ROP Invest Ophthalmol Vis S","volume":"52","author":"Raizada","year":"2011","journal-title":"ci"},{"key":"R28-11-20210130","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1542\/peds.2005-2749","article-title":"American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity.","volume":"117","year":"2006","journal-title":"Pediatrics"},{"key":"R29-11-20210130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited.","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R30-11-20210130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1542\/peds.89.1.91","article-title":". The Denver II: a major revision and restandardization of the Denver Developmental Screening Test.","volume":"89","author":"Frankenburg","year":"1992","journal-title":"Pediatrics"},{"key":"R31-11-20210130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-1231","article-title":"Disabilities; Section on Developmental Behavioral Pediatrics; Bright Futures Steering Committee; Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening.","volume":"118","year":"2006","journal-title":"Pediatrics"},{"key":"R32-11-20210130","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial.","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R33-11-20210130","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archopht.119.8.1110","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity; ophthalmological outcome 10 years.","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R34-11-20210130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.123.3.311","article-title":"; Cryotherapy for Retinopathy of Prematurity Cooperative Group. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity.","volume":"123","author":"Palmer","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R35-11-20210130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/bjo.2003.022962","article-title":"Late onset vitreoretinal complications of regressed retinopathy of prematurity.","volume":"88","author":"Tufail","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R36-11-20210130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bjo.81.1.12","article-title":"Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study.","volume":"81","author":"Laws","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"R37-11-20210130","first-page":"76","article-title":"UK retinopathy of prematurity treatment survey.","volume":"7","author":"Cuthbertson","year":"2006","journal-title":"Eye"},{"key":"R38-11-20210130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity.","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R39-11-20210130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0002-9394(01)00956-4","article-title":"Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome.","volume":"132","author":"Shalev","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R40-11-20210130","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","article-title":". VEGF is required for growth and survival in neonatal mice.","volume":"126","author":"Gerber","year":"1999","journal-title":"Development"},{"key":"R41-11-20210130","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":". Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R42-11-20210130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":". Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R43-11-20210130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","article-title":". Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors. A Childrens Oncology Group Study.","volume":"26","author":"Glade-Bender","year":"2008","journal-title":"J Clin Oncol"},{"key":"R44-11-20210130","first-page":"2021","article-title":". Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats.","volume":"43","author":"Bocker-Meffert","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R45-11-20210130","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1167\/iovs.06-0114","article-title":"Ocular growth and refractive error development in premature infants with or without retinopathy of prematurity.","volume":"49","author":"Cook","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R46-11-20210130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/bjo.84.2.138","article-title":"Long term refractive outcome in eyes of preterm infants with and without retinopathy of prematurity: comparison of keratometric value, axial length, anterior chamber depth, and lens thickness.","volume":"84","author":"Choi","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R48-11-20210130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.2004.045815","article-title":"Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months.","volume":"89","author":"Sahni","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R49-11-20210130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaapos.2006.05.005","article-title":"Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity.","volume":"10","author":"McLoone","year":"2006","journal-title":"J AAPOS"},{"key":"R50-11-20210130","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1167\/iovs.10-5234","article-title":". Long-term evaluation of refractive status and optical components in eyes of children born prematurely.","volume":"51","author":"Chen","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R51-11-20210130","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1167\/iovs.07-1226","article-title":"The cone electroretinogram in retinopathy of prematurity.","volume":"49","author":"Fulton","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R52-11-20210130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00006982-199515010-00004","article-title":"Electroretinographic findings in stage 5 retinopathy of prematurity after retinal reattachment.","volume":"15","author":"Cherry","year":"1995","journal-title":"Retina"},{"key":"R53-11-20210130","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.292.19.2357","article-title":". Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection.","volume":"292","author":"Stoll","year":"2004","journal-title":"JAMA"},{"key":"R54-11-20210130","doi-asserted-by":"crossref","first-page":"e899","DOI":"10.1542\/peds.2011-0282","article-title":". Infant growth before and after term: effects on neurodevelopment in preterm infants.","volume":"128","author":"Belfort","year":"2011","journal-title":"Pediatrics"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006982-201302000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T14:24:13Z","timestamp":1643552653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201302000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318275394a","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}